NYSE:OGN Organon & Co. (OGN) Stock Price, News & Analysis $12.21 +0.09 (+0.74%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$12.23 +0.02 (+0.16%) As of 04/25/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Organon & Co. Stock (NYSE:OGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organon & Co. alerts:Sign Up Key Stats Today's Range$11.91▼$12.2650-Day Range$10.67▼$16.1852-Week Range$10.45▼$23.10Volume2.73 million shsAverage Volume2.72 million shsMarket Capitalization$3.15 billionP/E Ratio3.67Dividend Yield9.17%Price Target$20.60Consensus RatingHold Company OverviewOrganon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Read More… Organon & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreOGN MarketRank™: Organon & Co. scored higher than 95% of companies evaluated by MarketBeat, and ranked 61st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingOrganon & Co. has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageOrganon & Co. has only been the subject of 2 research reports in the past 90 days.Read more about Organon & Co.'s stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth1.63% Earnings GrowthEarnings for Organon & Co. are expected to grow by 1.63% in the coming year, from $3.68 to $3.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organon & Co. is 3.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Organon & Co. is 3.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.39.Price to Earnings Growth RatioOrganon & Co. has a PEG Ratio of 0.90. PEG Ratios below 1 indicate that a company could be undervalued.Read more about Organon & Co.'s valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.78% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Organon & Co. has recently increased by 15.20%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipOrganon & Co. is a leading dividend payer. It pays a dividend yield of 9.75%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOrganon & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Organon & Co. is 33.63%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Organon & Co. will have a dividend payout ratio of 29.95% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.Read more about Organon & Co.'s dividend. Sustainability and ESG3.7 / 5Environmental Score-2.37 Percentage of Shares Shorted6.78% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Organon & Co. has recently increased by 15.20%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.10 News SentimentOrganon & Co. has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Organon & Co. this week, compared to 6 articles on an average week.Search InterestOnly 23 people have searched for OGN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows12 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organon & Co. insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Organon & Co. is held by insiders.Percentage Held by Institutions77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organon & Co.'s insider trading history. Receive OGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter. Email Address OGN Stock News HeadlinesOrganon (OGN) Receives a Sell from Bank of America SecuritiesApril 22, 2025 | markets.businessinsider.comOrganon Appoints Ramona A. Sequeira to the Company’s Board of DirectorsApril 15, 2025 | finance.yahoo.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 27, 2025 | American Alternative (Ad)Organon Appoints Ramona A. Sequeira to the Company's Board of DirectorsApril 15, 2025 | businesswire.comOrganon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025April 15, 2025 | businesswire.comOrganon price target lowered to $15 from $16 at Morgan StanleyApril 9, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Its Hold Rating for Organon (OGN)April 9, 2025 | markets.businessinsider.comOrganon acquires rights for Tofidence from BiogenApril 2, 2025 | markets.businessinsider.comSee More Headlines OGN Stock Analysis - Frequently Asked Questions How have OGN shares performed this year? Organon & Co.'s stock was trading at $14.92 at the beginning of 2025. Since then, OGN stock has decreased by 18.2% and is now trading at $12.21. View the best growth stocks for 2025 here. How were Organon & Co.'s earnings last quarter? Organon & Co. (NYSE:OGN) posted its earnings results on Thursday, February, 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by $0.09. The firm earned $1.59 billion during the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a trailing twelve-month return on equity of 431.62% and a net margin of 13.49%. Read the conference call transcript. Who are Organon & Co.'s major shareholders? Top institutional investors of Organon & Co. include Philip James Wealth Mangement LLC (0.34%), Sound Income Strategies LLC (0.26%), Gilman Hill Asset Management LLC (0.25%) and Rhumbline Advisers (0.20%). View institutional ownership trends. How do I buy shares of Organon & Co.? Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organon & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM). Company Calendar Last Earnings2/13/2025Record date for 3/13 Dividend2/24/2025Ex-Dividend for 3/13 Dividend2/24/2025Dividend Payable3/13/2025Today4/27/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGN CIK1821825 Webwww.organon.com Phone551-430-6900FaxN/AEmployees10,000Year FoundedN/APrice Target and Rating Average Stock Price Target$20.60 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside+68.7%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$3.33 Trailing P/E Ratio3.67 Forward P/E Ratio3.32 P/E Growth0.9Net Income$864 million Net Margins13.49% Pretax Margin12.60% Return on Equity431.62% Return on Assets8.03% Debt Debt-to-Equity Ratio17.73 Current Ratio1.70 Quick Ratio1.21 Sales & Book Value Annual Sales$6.40 billion Price / Sales0.49 Cash Flow$3.91 per share Price / Cash Flow3.12 Book Value($0.27) per share Price / Book-45.22Miscellaneous Outstanding Shares257,950,000Free Float253,933,000Market Cap$3.15 billion OptionableNot Optionable Beta0.73 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:OGN) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.